{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:23:49Z","timestamp":1791685429694,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":22,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","award":["W81XWH-19-1-0329"],"award-info":[{"award-number":["W81XWH-19-1-0329"]}],"id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017932","name":"Western University of Health Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017932","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s13311-023-01407-y","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T13:02:10Z","timestamp":1689858130000},"page":"1592-1602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Calpain-2 Inhibitors as Therapy for Traumatic Brain Injury"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5142-241X","authenticated-orcid":false,"given":"Michel","family":"Baudry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Lyna","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1007\/s13311-023-01407-y_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s40263-015-0225-3","article-title":"Taming glutamate excitotoxicity: strategic pathway modulation for neuroprotection","volume":"29","author":"Jia","year":"2015","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1007\/s13311-023-01407-y_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1602\/neurorx.1.1.101","article-title":"Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults","volume":"1","author":"Lipton","year":"2004","journal-title":"NeuroRx"},{"issue":"10","key":"10.1007\/s13311-023-01407-y_bib3","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nrn2911","article-title":"Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders","volume":"11","author":"Hardingham","year":"2010","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"10.1007\/s13311-023-01407-y_bib4","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.neuron.2014.03.030","article-title":"Extrasynaptic NMDA receptor involvement in central nervous system disorders","volume":"82","author":"Parsons","year":"2014","journal-title":"Neuron"},{"issue":"1","key":"10.1007\/s13311-023-01407-y_bib5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12035-008-8036-x","article-title":"Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration","volume":"38","author":"Vosler","year":"2008","journal-title":"Mol Neurobiol"},{"key":"10.1007\/s13311-023-01407-y_bib6","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2147\/NDT.S78226","article-title":"Neuroprotective strategies against calpain-mediated neurodegeneration","volume":"11","author":"Yildiz-Unal","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"2","key":"10.1007\/s13311-023-01407-y_bib7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.neuroscience.2008.09.007","article-title":"A novel calpain inhibitor,((1S)-1 ((((1S)-1-benzyl-3-cyclopropylamino-2, 3-di-oxopropyl) amino) carbonyl)-3-methylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced damage in mice","volume":"157","author":"Koumura","year":"2008","journal-title":"Neuroscience"},{"issue":"1","key":"10.1007\/s13311-023-01407-y_bib8","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbrc.2009.04.141","article-title":"A novel calpastatin-based inhibitor improves postischemic neurological recovery","volume":"385","author":"Anagli","year":"2009","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1007\/s13311-023-01407-y_bib9","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/02699052.2013.860479","article-title":"The role of calpains in traumatic brain injury","volume":"28","author":"Liu","year":"2014","journal-title":"Brain Inj"},{"key":"10.1007\/s13311-023-01407-y_bib10","series-title":"Brain neurotrauma: molecular, neuropsychological, and rehabilitation aspects","article-title":"Potential use of calpain inhibitors as brain injury therapy.","author":"Cagmat","year":"2015"},{"issue":"6","key":"10.1007\/s13311-023-01407-y_bib11","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.apsb.2015.08.001","article-title":"Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors","volume":"5","author":"Siklos","year":"2015","journal-title":"Acta Pharmaceutica Sinica B"},{"key":"10.1007\/s13311-023-01407-y_bib12","series-title":"Potential use of calpain inhibitors as brain injury therapy","author":"Cagmat","year":"2015"},{"issue":"12","key":"10.1007\/s13311-023-01407-y_bib13","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1089\/neu.2010.1474","article-title":"A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model","volume":"27","author":"Thompson","year":"2010","journal-title":"J Neurotrauma"},{"issue":"1","key":"10.1007\/s13311-023-01407-y_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/jnc.12118","article-title":"Pharmacological analysis of the cortical neuronal cytoskeletal protective efficacy of the calpain inhibitor SNJ-1945 in a mouse traumatic brain injury model","volume":"125","author":"Bains","year":"2013","journal-title":"J Neurochem"},{"issue":"6","key":"10.1007\/s13311-023-01407-y_bib15","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/jnc.12144","article-title":"Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse","volume":"125","author":"Schoch","year":"2013","journal-title":"J Neurochem"},{"issue":"8","key":"10.1007\/s13311-023-01407-y_bib16","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.93.8.3428","article-title":"Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat","volume":"93","author":"Saatman","year":"1996","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"1","key":"10.1007\/s13311-023-01407-y_bib17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/00004647-200001000-00010","article-title":"Behavioral efficacy of posttraumatic calpain inhibition is not accompanied by reduced spectrin proteolysis, cortical lesion, or apoptosis","volume":"20","author":"Saatman","year":"2000","journal-title":"J Cereb Blood Flow Metab."},{"issue":"3","key":"10.1007\/s13311-023-01407-y_bib18","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/089771503321532842","article-title":"Preinjury administration of the calpain inhibitor MDL-28170 attenuates traumatically induced axonal injury","volume":"20","author":"Buki","year":"2003","journal-title":"J Neurotrauma."},{"issue":"6","key":"10.1007\/s13311-023-01407-y_bib19","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1089\/neu.2006.0224","article-title":"Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury","volume":"24","author":"Ai","year":"2007","journal-title":"J Neurotrauma"},{"issue":"2","key":"10.1007\/s13311-023-01407-y_bib20","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1089\/neu.2011.2060","article-title":"Short-duration treatment with the calpain inhibitor MDL-28170 does not protect axonal transport in an in vivo model of traumatic axonal injury","volume":"29","author":"Ma","year":"2012","journal-title":"J Neurotrauma."},{"issue":"5","key":"10.1007\/s13311-023-01407-y_bib21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/13543776.2011.568480","article-title":"Calpain inhibitors: a survey of compounds reported in the patent and scientific literature","volume":"21","author":"Donkor","year":"2011","journal-title":"Expert Opin Ther Pat"},{"key":"10.1007\/s13311-023-01407-y_bib22","article-title":"Calpain-1 and calpain-2: the yin and yang of synaptic plasticity and neurodegeneration","volume":"10","author":"Baudry","year":"2016","journal-title":"Trends Neurosci."},{"issue":"48","key":"10.1007\/s13311-023-01407-y_bib23","doi-asserted-by":"crossref","first-page":"18880","DOI":"10.1523\/JNEUROSCI.3293-13.2013","article-title":"Distinct roles for mu-calpain and m-calpain in synaptic NMDAR-mediated neuroprotection and extrasynaptic NMDAR-mediated neurodegeneration","volume":"33","author":"Wang","year":"2013","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-023-01407-y_bib24","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1038\/ncomms4051","article-title":"A molecular brake controls the magnitude of long-term potentiation","volume":"5","author":"Wang","year":"2014","journal-title":"Nat Commun"},{"issue":"20","key":"10.1007\/s13311-023-01407-y_bib25","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1021\/jm950541c","article-title":"Novel peptidyl \u03b1-keto amide inhibitors of calpains and other cysteine proteases","volume":"39","author":"Li","year":"1996","journal-title":"J Med Chem"},{"key":"10.1007\/s13311-023-01407-y_bib26","article-title":"Protection against TBI-induced neuronal death with post-treatment with a selective calpain-2 inhibitor in mice","author":"Wang","year":"2017","journal-title":"J Neurotrauma."},{"issue":"1","key":"10.1007\/s13311-023-01407-y_bib27","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/syn.890010105","article-title":"Calmodulin stimulates the degradation of brain spectrin by calpain","volume":"1","author":"Seubert","year":"1987","journal-title":"Synapse"},{"issue":"10","key":"10.1007\/s13311-023-01407-y_bib28","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1523\/JNEUROSCI.4907-12.2013","article-title":"Calpain-2-mediated PTEN degradation contributes to BDNF-induced stimulation of dendritic protein synthesis","volume":"33","author":"Briz","year":"2013","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-023-01407-y_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.nbd.2016.05.007","article-title":"Calpain-1 and calpain-2 play opposite roles in retinal ganglion cell degeneration induced by retinal ischemia\/reperfusion injury","volume":"93","author":"Wang","year":"2016","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-023-01407-y_bib30","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3389\/fneur.2013.00190","article-title":"Evidence that the blood biomarker SNTF predicts brain imaging changes and persistent cognitive dysfunction in mild TBI patients","volume":"4","author":"Siman","year":"2013","journal-title":"Front Neurol"},{"key":"10.1007\/s13311-023-01407-y_bib31","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3389\/fneur.2020.00249","article-title":"Serum SNTF, a surrogate marker of axonal injury, is prognostic for lasting brain dysfunction in mild TBI treated in the emergency department","volume":"11","author":"Siman","year":"2020","journal-title":"Front Neurol."},{"key":"10.1007\/s13311-023-01407-y_bib32","unstructured":"Siman R. SNTF is a blood biomarker for the diagnosis and prognosis of sports-related concussion. Google Patents; 2014."},{"issue":"12","key":"10.1007\/s13311-023-01407-y_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122698","article-title":"Calpain-1 and calpain-2 in the brain: new evidence for a critical role of calpain-2 in neuronal death","volume":"9","author":"Wang","year":"2020","journal-title":"Cells"},{"issue":"22","key":"10.1007\/s13311-023-01407-y_bib34","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1089\/neu.2021.0229","article-title":"P13BP, a calpain-2-mediated breakdown product of PTPN13, is a novel blood biomarker for traumatic brain injury","volume":"38","author":"Wang","year":"2021","journal-title":"J Neurotrauma."},{"issue":"2","key":"10.1007\/s13311-023-01407-y_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3171\/jns.1994.80.2.0301","article-title":"A new model of diffuse brain injury in rats: part II: morphological characterization","volume":"80","author":"Abd-Elfattah Foda","year":"1994","journal-title":"J Neurosurg"},{"key":"10.1007\/s13311-023-01407-y_bib36","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3389\/fneur.2019.00713","article-title":"Chronic traumatic encephalopathy: a brief overview","volume":"10","author":"Fesharaki-Zadeh","year":"2019","journal-title":"Front Neurol."},{"issue":"10","key":"10.1007\/s13311-023-01407-y_bib37","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1002\/jnr.24472","article-title":"Modeling sports-related mild traumatic brain injury in animals-a systematic review","volume":"97","author":"Hiskens","year":"2019","journal-title":"J Neurosci Res."},{"issue":"5","key":"10.1007\/s13311-023-01407-y_bib38","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.tins.2016.03.002","article-title":"Traumatic axonal injury: mechanisms and translational opportunities","volume":"39","author":"Hill","year":"2016","journal-title":"Trends Neurosci."},{"issue":"17","key":"10.1007\/s13311-023-01407-y_bib39","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1089\/neu.2014.3698","article-title":"Serum SNTF increases in concussed professional ice hockey players and relates to the severity of postconcussion symptoms","volume":"32","author":"Siman","year":"2015","journal-title":"J Neurotrauma."},{"issue":"13","key":"10.1007\/s13311-023-01407-y_bib40","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1089\/neu.2013.3255","article-title":"The spectrum of neurobehavioral sequelae after repetitive mild traumatic brain injury: a novel mouse model of chronic traumatic encephalopathy","volume":"31","author":"Petraglia","year":"2014","journal-title":"J Neurotrauma"},{"key":"10.1007\/s13311-023-01407-y_bib41","doi-asserted-by":"crossref","DOI":"10.4103\/2152-7806.147566","article-title":"The pathophysiology underlying repetitive mild traumatic brain injury in a novel mouse model of chronic traumatic encephalopathy","volume":"5","author":"Petraglia","year":"2014","journal-title":"Surg Neurol Int."},{"issue":"27","key":"10.1007\/s13311-023-01407-y_bib42","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aba5547","article-title":"Calpain-2 as a therapeutic target in repeated concussion-induced neuropathy and behavioral impairment","volume":"6","author":"Wang","year":"2020","journal-title":"Sci Adv."},{"issue":"27","key":"10.1007\/s13311-023-01407-y_bib43","doi-asserted-by":"crossref","first-page":"9858","DOI":"10.1523\/JNEUROSCI.0560-11.2011","article-title":"Pathogenic forms of tau inhibit kinesin-dependent axonal transport through a mechanism involving activation of axonal phosphotransferases","volume":"31","author":"Kanaan","year":"2011","journal-title":"J Neurosci."},{"issue":"1","key":"10.1007\/s13311-023-01407-y_bib44","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/jnen\/nlv001","article-title":"Characterization of early pathological tau conformations and phosphorylation in chronic traumatic encephalopathy","volume":"75","author":"Kanaan","year":"2015","journal-title":"J Neuropathol Exp Neurol"},{"issue":"4","key":"10.1007\/s13311-023-01407-y_bib45","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/path.1645","article-title":"Astrocyte intermediate filaments in CNS pathologies and regeneration","volume":"204","author":"Pekny","year":"2004","journal-title":"J Pathol."},{"issue":"1","key":"10.1007\/s13311-023-01407-y_bib46","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1038\/s41598-017-01747-8","article-title":"Characterizing microglia activation: a spatial statistics approach to maximize information extraction","volume":"7","author":"Davis","year":"2017","journal-title":"Sci Rep."},{"key":"10.1007\/s13311-023-01407-y_bib47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jneumeth.2018.07.021","article-title":"A novel repetitive mild traumatic brain injury mouse model for chronic traumatic encephalopathy research","volume":"308","author":"Ge","year":"2018","journal-title":"J Neurosci Methods"},{"issue":"4","key":"10.1007\/s13311-023-01407-y_bib48","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nrneurol.2010.18","article-title":"TAR DNA-binding protein 43 in neurodegenerative disease","volume":"6","author":"Chen-Plotkin","year":"2010","journal-title":"Nat Rev Neurol."},{"key":"10.1007\/s13311-023-01407-y_bib49","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1038\/ncomms2303","article-title":"A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology","volume":"3","author":"Yamashita","year":"2012","journal-title":"Nat Commun."},{"issue":"8","key":"10.1007\/s13311-023-01407-y_bib50","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1136\/jnnp-2018-320106","article-title":"Neurofilament light chain as a biomarker in neurological disorders","volume":"90","author":"Gaetani","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"17","key":"10.1007\/s13311-023-01407-y_bib51","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1021\/jm901221v","article-title":"Peptidyl \u03b1-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors","volume":"53","author":"Ovat","year":"2010","journal-title":"J Med Chem"},{"issue":"49","key":"10.1007\/s13311-023-01407-y_bib52","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1021\/jacs.7b08938","article-title":"Can relative binding free energy predict selectivity of reversible covalent inhibitors?","volume":"139","author":"Chatterjee","year":"2017","journal-title":"J Am Chem Soc"},{"issue":"5","key":"10.1007\/s13311-023-01407-y_bib53","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1021\/acs.jcim.8b00959","article-title":"Ranking reversible covalent drugs: from free energy perturbation to fragment docking","volume":"59","author":"Zhang","year":"2019","journal-title":"J Chem Inf Model"},{"issue":"11","key":"10.1007\/s13311-023-01407-y_bib54","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1021\/acs.jcim.1c01278","article-title":"Mechanism-based and computational-driven covalent drug design","volume":"61","author":"Luo","year":"2021","journal-title":"J Chem Inf Model"},{"issue":"6","key":"10.1007\/s13311-023-01407-y_bib55","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1021\/acs.jcim.9b00210","article-title":"Optimization and evaluation of site-identification by ligand competitive saturation (SILCS) as a tool for target-based ligand optimization","volume":"59","author":"Ustach","year":"2019","journal-title":"J Chem Inf Model"},{"key":"10.1007\/s13311-023-01407-y_bib56","doi-asserted-by":"crossref","unstructured":"Baudry M, Wang Y, Bi X, Luo Y, Kamal Z, Shirokov A, Sullivan E, Lagasca D, HKhalil H, Lee G, Fosnaugh K, Bey P, Medi S, Coulter G, et al. Identification and properties of NA-184, a selective calpain-2 inhibitor, and its use for TBI treatment. Society for Neuroscience Meeting; 2022; San Diego.","DOI":"10.1101\/2023.10.16.562509"},{"key":"10.1007\/s13311-023-01407-y_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105149","article-title":"Calpain-2 activation in mouse hippocampus plays a critical role in seizure-induced neuropathology","volume":"147","author":"Wang","year":"2021","journal-title":"Neurobiol Dis."},{"key":"10.1007\/s13311-023-01407-y_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/srep01224","article-title":"Post-natal treatment by a blood-brain-barrier permeable calpain inhibitor, SNJ1945 rescued defective function in lissencephaly","volume":"3","author":"Toba","year":"2013","journal-title":"Sci Rep."},{"issue":"4","key":"10.1007\/s13311-023-01407-y_bib59","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.neuropharm.2010.07.013","article-title":"Calpain inhibition prevents amyloid-\u03b2-induced neurodegeneration and associated behavioral dysfunction in rats","volume":"59","author":"Granic","year":"2010","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1007\/s13311-023-01407-y_bib60","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/cpdd.598","article-title":"Pharmacokinetics, safety, tolerability, and pharmacodynamics of alicapistat, a selective inhibitor of human calpains 1 and 2 for the treatment of Alzheimer disease: an overview of phase 1 studies","volume":"8","author":"Lon","year":"2019","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"17","key":"10.1007\/s13311-023-01407-y_bib61","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1021\/jm901221v","article-title":"Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors","volume":"53","author":"Ovat","year":"2010","journal-title":"J Med Chem."},{"issue":"1","key":"10.1007\/s13311-023-01407-y_bib62","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1517\/13543776.2014.982534","article-title":"An updated patent review of calpain inhibitors (2012\u20132014)","volume":"25","author":"Donkor","year":"2015","journal-title":"Expert Opin Ther Pat"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01407-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-023-01407-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923019992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-023-01407-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:17:46Z","timestamp":1761808666000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923019992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1878747923019992"],"URL":"https:\/\/doi.org\/10.1007\/s13311-023-01407-y","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calpain-2 Inhibitors as Therapy for Traumatic Brain Injury","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-023-01407-y","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 The Author(s). Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}